Papatheodoridi M. Rates and predictors of HBsAg loss after discontinuation of effective long-term Entecavir or Tenofovir therapy in non-cirrhotic HBeAg-negative Chronic Hepatitis B patients: Results from the DARING-B prospective Greek study. PS-159.
Highlights IDWeek 2023
nov 2023 | Bacteriële infecties, HIV, Parasitaire infecties, SOA, Vaccinatie, Virale infecties